Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf, to simplify, standardize, and automate cell therapy manufacturing.
Cellular Origins’ and ScaleReady’s first project will be to standardize and automate interconnections between the modules of ScaleReady’s G-Rex®, a manufacturing platform used by therapy developers internationally to produce cell and gene therapies for clinical trials.
Dr Edwin Stone, CEO of Cellular Origins, elaborated on the wide technologies of ScaleReady being utilized in the production of advanced, cell-based therapies:
“This collaboration demonstrates the adaptability of our robotic system, highlighting that it can be integrated seamlessly into existing workflows and allowing therapy developers access to scalable, cost-effective advanced therapy manufacture without significant process redevelopment.”
The integration of Cellular Origin’s robotic system will support ScaleReady’s beliefs of simplicity and repeatability in practical scaling of CGT manufacturing. Automation has the potential to improve the process of sterile interconnections, an area where labor is dependent. Leveraging of Cellular Origins’ robotic system will eliminate variability in manual connection technique.
“Our partnership with Cellular Origins is an important step towards ScaleReady’s mission to simplify and standardize CGT manufacture, solving the liquid handling problem and proving how amenable a simple, modular, and scalable approach is to automation allows the field to see a path forward to economies of scale,” added Josh Ludwig, Commercial Director at ScaleReady.
Further projects will automate additional components of ScaleReady’s workflow, such as the robotic movement of G-Rex® into and out of incubators.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.